Wheeler Bio Announces Strategic Partnership with Mitsubishi Corporation to Accelerate Asia‑Pacific Business Development
Wheeler Bio, Inc., a U.S. based CDMO specializing in antibody‑based therapeutics, has entered into a strategic partnership with Mitsubishi Corporation, under which Mitsubishi will invest in Wheeler’s Series A‑1 financing and act as its exclusive commercialization partner across key Asia‑Pacific markets including Japan, South Korea, India, Singapore, Taiwan and China. The collaboration leverages Mitsubishi’s regional network and industry expertise to connect APAC biotech innovators with Wheeler’s U.S.‑based development and cGMP manufacturing capabilities via its AI/ML‑enabled ModularCMC™ platform.
Wheeler Bio Announces Strategic Partnership with Mitsubishi Corporation to Accelerate Asia‑Pacific Business Development